Publications
45
Citations
720
Est. group size
—
Recurring co-author estimate
Active years
11
Publishing since 2015
Typically publishes in teams of ~5 · 23% small-team papers (≤3 authors) · across 23 venues
- The pharmacokinetics of antibiotics in patients with obesity: a systematic review and consensus guidelines for dose adjustments
The Lancet Infectious Diseases · 2025
- Population Pharmacokinetic and Exposure‐Efficacy Analyses of Valbenazine in Patients with Huntington's Disease: Supporting Dose Selection for Chorea Management
The Journal of Clinical Pharmacology · 2025
- Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria
Drugs in R&D · 2024
- A Model‐Informed Drug Development Approach Supporting the Approval of an Unstudied Valbenazine Dose for Patients With Tardive Dyskinesia
The Journal of Clinical Pharmacology · 2024
- Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham
CPT Pharmacometrics & Systems Pharmacology · 2024
- Population Pharmacokinetics of Pegcetacoplan in Patients with Geographic Atrophy or Neovascular Age-related Macular Degeneration
Ophthalmology Science · 2024
- Use of Model-informed Drug Development and Natural History Data to Inform the Development of Iluzanebart in ALSP: A Neurological Rare Disease
2024
- Population Pharmacokinetic and Exposure-Response Analyses of Valbenazine in Patients with Huntington’s Disease Chorea
2024
- Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia
Journal of Pharmacokinetics and Pharmacodynamics · 2023
- PB2053: POPULATION PHARMACOKINETICS OF PEGCETACOPLAN IN HEALTHY SUBJECTS AND PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
HemaSphere · 2023
- PB2054: EXPOSURE-RESPONSE ANALYSES OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
HemaSphere · 2023
- Population pharmacokinetics model of apomorphine (sublingual film or subcutaneous injection) in healthy subjects and patients with Parkinson’s disease (updated)
Parkinsonism & Related Disorders · 2023
- Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose–response model
European Heart Journal - Cardiovascular Pharmacotherapy · 2021
- Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19
Clinical Pharmacokinetics · 2021
- Alteration in Acute Kidney Injury Potential with the Combination of Vancomycin and Imipenem-Cilastatin/Relebactam or Piperacillin/Tazobactam in a Preclinical Model
Antimicrobial Agents and Chemotherapy · 2021
- Antimicrobial Agents and Chemotherapy×6
- Open Forum Infectious Diseases×4
- Journal of Antimicrobial Chemotherapy×3
- The Journal of Clinical Pharmacology×3
- Clinical Pharmacokinetics×2
- Manjunath P. Pai
Medicine · University of Michigan
- Bruce A. Mueller
Medicine · University of Michigan
- Michael Kays
Medicine · Purdue University West Lafayette
- Sharon M. Erdman
Medicine · Purdue University West Lafayette
- Kevin M. Sowinski
Medicine · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile